

Jose C Florez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3224196/publications.pdf>

Version: 2024-02-01

168
papers

41,508
citations

8159

76
h-index

5965

160
g-index

188
all docs

188
docs citations

188
times ranked

55929
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic analysis of dietary intake identifies new loci and functional links with metabolic traits. <i>Nature Human Behaviour</i> , 2022, 6, 155-163.	6.2	22
2	Heterogeneity of Diabetes: Î²-Cells, Phenotypes, and Precision Medicine: Proceedings of an International Symposium of the Canadian Institutes of Health Researchâ€™s Institute of Nutrition, Metabolism and Diabetes and the U.S. National Institutes of Healthâ€™s National Institute of Diabetes and Digestive and Kidney Diseases. <i>Diabetes Care</i> , 2022, 45, 3-22.	4.3	14
3	Recessive Genome-Wide Meta-analysis Illuminates Genetic Architecture of Type 2 Diabetes. <i>Diabetes</i> , 2022, 71, 554-565.	0.3	7
4	Interplay of Dinner Timing and <i>MTNR1B</i> Type 2 Diabetes Risk Variant on Glucose Tolerance and Insulin Secretion: A Randomized Crossover Trial. <i>Diabetes Care</i> , 2022, 45, 512-519.	4.3	26
5	Type 2 Diabetes Partitioned Polygenic Scores Associate With Disease Outcomes in 454,193 Individuals Across 13 Cohorts. <i>Diabetes Care</i> , 2022, 45, 674-683.	4.3	29
6	Genetics in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2022, 101, 1126-1141.	2.6	46
7	Polygenic scores, diet quality, and type 2 diabetes risk: An observational study among 35,759 adults from 3 US cohorts. <i>PLoS Medicine</i> , 2022, 19, e1003972.	3.9	17
8	Extending precision medicine tools to populations at high risk of type 2 diabetes. <i>PLoS Medicine</i> , 2022, 19, e1003989.	3.9	1
9	A roadmap to achieve pharmacological precision medicine in diabetes. <i>Diabetologia</i> , 2022, 65, 1830-1838.	2.9	16
10	Association of <i>GLP1R</i> Polymorphisms With the Incretin Response. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2580-2588.	1.8	2
11	Genome-wide meta-analysis and omics integration identifies novel genes associated with diabetic kidney disease. <i>Diabetologia</i> , 2022, 65, 1495-1509.	2.9	16
12	Variance-quantitative trait loci enable systematic discovery of gene-environment interactions for cardiometabolic serum biomarkers. <i>Nature Communications</i> , 2022, 13, .	5.8	14
13	Genetic Loci and Physiologic Pathways Involved in Gestational Diabetes Mellitus Implicated Through Clustering. <i>Diabetes</i> , 2021, 70, 268-281.	0.3	10
14	A Polygenic Score for Type 2 Diabetes Risk Is Associated With Both the Acute and Sustained Response to Sulfonylureas. <i>Diabetes</i> , 2021, 70, 293-300.	0.3	22
15	Cardiometabolic risk factors for COVID-19 susceptibility and severity: A Mendelian randomization analysis. <i>PLoS Medicine</i> , 2021, 18, e1003553.	3.9	105
16	The impact of non-additive genetic associations on age-related complex diseases. <i>Nature Communications</i> , 2021, 12, 2436.	5.8	55
17	The trans-ancestral genomic architecture of glycemic traits. <i>Nature Genetics</i> , 2021, 53, 840-860.	9.4	341
18	Determinants of penetrance and variable expressivity in monogenic metabolic conditions across 77,184 exomes. <i>Nature Communications</i> , 2021, 12, 3505.	5.8	49

#	ARTICLE	IF	CITATIONS
19	Monogenic Diabetes in Youth With Presumed Type 2 Diabetes: Results From the Progress in Diabetes Genetics in Youth (ProDiGY) Collaboration. <i>Diabetes Care</i> , 2021, 44, 2312-2319.	4.3	21
20	The First Genome-Wide Association Study for Type 2 Diabetes in Youth: The Progress in Diabetes Genetics in Youth (ProDiGY) Consortium. <i>Diabetes</i> , 2021, 70, 996-1005.	0.3	37
21	Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. <i>Diabetes Care</i> , 2021, 44, 2673-2682.	4.3	23
22	Genome-wide association analyses highlight etiological differences underlying newly defined subtypes of diabetes. <i>Nature Genetics</i> , 2021, 53, 1534-1542.	9.4	81
23	Interaction Between Type 2 Diabetes Prevention Strategies and Genetic Determinants of Coronary Artery Disease on Cardiometabolic Risk Factors. <i>Diabetes</i> , 2020, 69, 112-120.	0.3	13
24	The Need for Precision Medicine to be Applied to Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2020, 14, 1122-1128.	1.3	10
25	Large-Scale, Genome-Wide Gene-Diet Interaction Testing for HbA1c Using Derived Dietary Patterns in the UK Biobank. <i>Current Developments in Nutrition</i> , 2020, 4, nzaa058_038.	0.1	0
26	Smoking-by-genotype interaction in type 2 diabetes risk and fasting glucose. <i>PLoS ONE</i> , 2020, 15, e0230815.	1.1	10
27	Genetics of diabetes mellitus and diabetes complications. <i>Nature Reviews Nephrology</i> , 2020, 16, 377-390.	4.1	657
28	Advancing Dinner Timing Is an Effective Strategy in Improving Glucose Tolerance in Free-Living Adults: A Randomized Cross-Over Trial. <i>Current Developments in Nutrition</i> , 2020, 4, nzaa047_005.	0.1	0
29	Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2020, 63, 1671-1693.	2.9	102
30	Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2020, 43, 1617-1635.	4.3	204
31	Genome-wide meta-analysis of macronutrient intake of 91,114 European ancestry participants from the cohorts for heart and aging research in genomic epidemiology consortium. <i>Molecular Psychiatry</i> , 2019, 24, 1920-1932.	4.1	44
32	Quality of dietary fat and genetic risk of type 2 diabetes: individual participant data meta-analysis. <i>BMJ: British Medical Journal</i> , 2019, 366, l4292.	2.4	28
33	Gain-of-Function Claims for Type-2-Diabetes-Associated Coding Variants in SLC16A11 Are Not Supported by the Experimental Data. <i>Cell Reports</i> , 2019, 29, 778-780.	2.9	6
34	Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2000-2016.	3.0	135
35	Metabolite Profiles of Incident Diabetes and Heterogeneity of Treatment Effect in the Diabetes Prevention Program. <i>Diabetes</i> , 2019, 68, 2337-2349.	0.3	22
36	A Polygenic Lipodystrophy Genetic Risk Score Characterizes Risk Independent of BMI in the Diabetes Prevention Program. <i>Journal of the Endocrine Society</i> , 2019, 3, 1663-1677.	0.1	13

#	ARTICLE	IF	CITATIONS
37	Genetic Risk Scores for Diabetes Diagnosis and Precision Medicine. <i>Endocrine Reviews</i> , 2019, 40, 1500-1520.	8.9	192
38	Polyunsaturated Fatty Acid Desaturation Is a Mechanism for Glycolytic NAD ⁺ Recycling. <i>Cell Metabolism</i> , 2019, 29, 856-870.e7.	7.2	87
39	Mendelian Randomization Analysis of Hemoglobin A1c as a Risk Factor for Coronary Artery Disease. <i>Diabetes Care</i> , 2019, 42, 1202-1208.	4.3	33
40	Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls. <i>Nature</i> , 2019, 570, 71-76.	13.7	248
41	0045 Decreased Oral Glucose Tolerance And Insulin Response During Biological Evening Versus Morning Among Adults Under Free-living Conditions. <i>Sleep</i> , 2019, 42, A18-A19.	0.6	0
42	SAT-123 Burden of Type 2 Diabetes Genetic Risk Alleles Differs Among Physiologic Subtypes of Gestational Diabetes Mellitus. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	5
43	Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. <i>Nature Genetics</i> , 2018, 50, 559-571.	9.4	356
44	Metabolomics insights into early type 2 diabetes pathogenesis and detection in individuals with normal fasting glucose. <i>Diabetologia</i> , 2018, 61, 1315-1324.	2.9	93
45	Precision medicine in diabetes: an opportunity for clinical translation. <i>Annals of the New York Academy of Sciences</i> , 2018, 1411, 140-152.	1.8	32
46	Re-analysis of public genetic data reveals a rare X-chromosomal variant associated with type 2 diabetes. <i>Nature Communications</i> , 2018, 9, 321.	5.8	85
47	<i>TCF7L2</i> Genetic Variation Augments Incretin Resistance and Influences Response to a Sulfonylurea and Metformin: The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH). <i>Diabetes Care</i> , 2018, 41, 554-561.	4.3	35
48	Genetic Evidence That Carbohydrate-Stimulated Insulin Secretion Leads to Obesity. <i>Clinical Chemistry</i> , 2018, 64, 192-200.	1.5	66
49	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. <i>Diabetes</i> , 2018, 67, 1414-1427.	0.3	136
50	Genetics and biobanks converge to resolve a vexing knowledge gap in diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 87-89.	5.5	0
51	Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. <i>Nature Genetics</i> , 2018, 50, 1505-1513.	9.4	1,331
52	Genetic Determinants of Glycemic Traits and the Risk of Gestational Diabetes Mellitus. <i>Diabetes</i> , 2018, 67, 2703-2709.	0.3	30
53	Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis. <i>PLoS Medicine</i> , 2018, 15, e1002654.	3.9	373
54	A Global Overview of Precision Medicine in Type 2 Diabetes. <i>Diabetes</i> , 2018, 67, 1911-1922.	0.3	90

#	ARTICLE	IF	CITATIONS
55	Mexican Carriers of the <i>HNF1A</i> p.E508K Variant Do Not Experience an Enhanced Response to Sulfonylureas. <i>Diabetes Care</i> , 2018, 41, 1726-1731.	4.3	14
56	Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool?. <i>Diabetologia</i> , 2017, 60, 800-807.	2.9	51
57	An Expanded Genome-Wide Association Study of Type 2 Diabetes in Europeans. <i>Diabetes</i> , 2017, 66, 2888-2902.	0.3	615
58	Mining the Genome for Therapeutic Targets. <i>Diabetes</i> , 2017, 66, 1770-1778.	0.3	14
59	Thyroid dysfunction in patients with Down syndrome: Results from a multi-institutional registry study. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 1539-1545.	0.7	34
60	Genetically Driven Hyperglycemia Increases Risk of Coronary Artery Disease Separately From Type 2 Diabetes. <i>Diabetes Care</i> , 2017, 40, 687-693.	4.3	45
61	A Loss-of-Function Splice Acceptor Variant in <i>IGF2</i> Is Protective for Type 2 Diabetes. <i>Diabetes</i> , 2017, 66, 2903-2914.	0.3	52
62	The pharmacogenetics of metformin. <i>Diabetologia</i> , 2017, 60, 1648-1655.	2.9	65
63	Type 2 Diabetes Variants Disrupt Function of <i>SLC16A11</i> through Two Distinct Mechanisms. <i>Cell</i> , 2017, 170, 199-212.e20.	13.5	121
64	The Genetic Landscape of Renal Complications in Type 1 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 557-574.	3.0	101
65	The Genetic Basis of Type 2 Diabetes in Hispanics and Latin Americans: Challenges and Opportunities. <i>Frontiers in Public Health</i> , 2017, 5, 329.	1.3	27
66	Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-analysis. <i>PLoS Medicine</i> , 2017, 14, e1002383.	3.9	341
67	Leveraging Genetics to Advance Type 2 Diabetes Prevention. <i>PLoS Medicine</i> , 2016, 13, e1002102.	3.9	17
68	The genetic architecture of type 2 diabetes. <i>Nature</i> , 2016, 536, 41-47.	13.7	952
69	Type 2 diabetes: genetic data sharing to advance complex disease research. <i>Nature Reviews Genetics</i> , 2016, 17, 535-549.	7.7	128
70	Personalized Comments on Challenges and Opportunities in Kidney Disease Therapeutics: The Glom-NExT Symposium. <i>Seminars in Nephrology</i> , 2016, 36, 448.	0.6	2
71	Genetics of Diabetic Kidney Disease. <i>Seminars in Nephrology</i> , 2016, 36, 474-480.	0.6	13
72	Heterogeneous Contribution of Insulin Sensitivity and Secretion Defects to Gestational Diabetes Mellitus. <i>Diabetes Care</i> , 2016, 39, 1052-1055.	4.3	142

#	ARTICLE	IF	CITATIONS
73	Found in Translation: A Type 1 Diabetes Genetic Risk Score Applied to Clinical Diagnosis. <i>Diabetes Care</i> , 2016, 39, 330-332.	4.3	7
74	FTO genotype and weight loss: systematic review and meta-analysis of 9563 individual participant data from eight randomised controlled trials. <i>BMJ, The</i> , 2016, 354, i4707.	3.0	88
75	Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. <i>Nature Genetics</i> , 2016, 48, 1055-1059.	9.4	165
76	Analysis of protein-coding genetic variation in 60,706 humans. <i>Nature</i> , 2016, 536, 285-291.	13.7	9,051
77	Genome-Wide Association Study of the Modified Stumvoll Insulin Sensitivity Index Identifies <i>BCL2</i> and <i>FAM19A2</i> as Novel Insulin Sensitivity Loci. <i>Diabetes</i> , 2016, 65, 3200-3211.	0.3	67
78	Precision Medicine in Diabetes: Is It Time?. <i>Diabetes Care</i> , 2016, 39, 1085-1088.	4.3	42
79	Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of the Genetic Burden of Established Insulin Resistance Variants in Diabetes Prevention Program Participants. <i>Diabetes</i> , 2016, 65, 520-526.	0.3	34
80	Genome-wide association studies in the Japanese population identify seven novel loci for type 2 diabetes. <i>Nature Communications</i> , 2016, 7, 10531.	5.8	149
81	Metabolite Profiles of Diabetes Incidence and Intervention Response in the Diabetes Prevention Program. <i>Diabetes</i> , 2016, 65, 1424-1433.	0.3	101
82	National down syndrome patient database: Insights from the development of a multi-center registry study. <i>American Journal of Medical Genetics, Part A</i> , 2015, 167, 2520-2526.	0.7	19
83	Pathways Targeted by Antidiabetes Drugs Are Enriched for Multiple Genes Associated With Type 2 Diabetes Risk. <i>Diabetes</i> , 2015, 64, 1470-1483.	0.3	31
84	Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility. <i>Nature Communications</i> , 2015, 6, 5897.	5.8	173
85	Genetic Predisposition to Weight Loss and Regain With Lifestyle Intervention: Analyses From the Diabetes Prevention Program and the Look AHEAD Randomized Controlled Trials. <i>Diabetes</i> , 2015, 64, 4312-4321.	0.3	72
86	Genetic Evidence for a Causal Role of Obesity in Diabetic Kidney Disease. <i>Diabetes</i> , 2015, 64, 4238-4246.	0.3	63
87	Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci. <i>Nature Genetics</i> , 2015, 47, 1415-1425.	9.4	365
88	The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH): Design of a pharmacogenetic Resource for Type 2 Diabetes. <i>PLoS ONE</i> , 2015, 10, e0121553.	1.1	20
89	Impact of Type 2 Diabetes Susceptibility Variants on Quantitative Glycemic Traits Reveals Mechanistic Heterogeneity. <i>Diabetes</i> , 2014, 63, 2158-2171.	0.3	297
90	Polygenic Type 2 Diabetes Prediction at the Limit of Common Variant Detection. <i>Diabetes</i> , 2014, 63, 2172-2182.	0.3	127

#	ARTICLE	IF	CITATIONS
91	Genetics of Drug Response in Diabetes. <i>Frontiers in Diabetes</i> , 2014, , 158-172.	0.4	1
92	Association of a Low-Frequency Variant in <i>HNF1A</i> With Type 2 Diabetes in a Latino Population. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2305.	3.8	230
93	An update on the pharmacogenomics of metformin: progress, problems and potential. <i>Pharmacogenomics</i> , 2014, 15, 529-539.	0.6	52
94	Sequence variants in <i>SLC16A11</i> are a common risk factor for type 2 diabetes in Mexico. <i>Nature</i> , 2014, 506, 97-101.	13.7	439
95	Effects of Weight Loss, Weight Cycling, and Weight Loss Maintenance on Diabetes Incidence and Change in Cardiometabolic Traits in the Diabetes Prevention Program. <i>Diabetes Care</i> , 2014, 37, 2738-2745.	4.3	97
96	Metformin Pharmacogenomics: Current Status and Future Directions. <i>Diabetes</i> , 2014, 63, 2590-2599.	0.3	112
97	Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. <i>Nature Genetics</i> , 2014, 46, 234-244.	9.4	959
98	Metabolite Traits and Genetic Risk Provide Complementary Information for the Prediction of Future Type 2 Diabetes. <i>Diabetes Care</i> , 2014, 37, 2508-2514.	4.3	87
99	Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes. <i>Nature Genetics</i> , 2013, 45, 1380-1385.	9.4	129
100	Pharmacogenetic Perturbations in Humans as a Tool to Generate Mechanistic Insight. <i>Diabetes</i> , 2013, 62, 3019-3021.	0.3	7
101	Gene-Environment and Gene-Treatment Interactions in Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 1413-1421.	4.3	128
102	Personalized Genetic Risk Counseling to Motivate Diabetes Prevention. <i>Diabetes Care</i> , 2013, 36, 13-19.	4.3	143
103	Chromosome 2q31.1 Associates with ESRD in Women with Type 1 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1537-1543.	3.0	66
104	2-Aminoadipic acid is a biomarker for diabetes risk. <i>Journal of Clinical Investigation</i> , 2013, 123, 4309-4317.	3.9	397
105	Novel Loci for Adiponectin Levels and Their Influence on Type 2 Diabetes and Metabolic Traits: A Multi-Ethnic Meta-Analysis of 45,891 Individuals. <i>PLoS Genetics</i> , 2012, 8, e1002607.	1.5	419
106	New Susceptibility Loci Associated with Kidney Disease in Type 1 Diabetes. <i>PLoS Genetics</i> , 2012, 8, e1002921.	1.5	216
107	The C Allele of <i>ATM</i> rs11212617 Does Not Associate With Metformin Response in the Diabetes Prevention Program. <i>Diabetes Care</i> , 2012, 35, 1864-1867.	4.3	65
108	Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. <i>Nature Genetics</i> , 2012, 44, 991-1005.	9.4	746

#	ARTICLE	IF	CITATIONS
109	No Interactions Between Previously Associated 2-Hour Glucose Gene Variants and Physical Activity or BMI on 2-Hour Glucose Levels. <i>Diabetes</i> , 2012, 61, 1291-1296.	0.3	23
110	Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. <i>Nature Genetics</i> , 2012, 44, 981-990.	9.4	1,748
111	Association Testing of Previously Reported Variants in a Large Case-Control Meta-analysis of Diabetic Nephropathy. <i>Diabetes</i> , 2012, 61, 2187-2194.	0.3	77
112	A Genome-Wide Association Search for Type 2 Diabetes Genes in African Americans. <i>PLoS ONE</i> , 2012, 7, e29202.	1.1	197
113	Effects of Genetic Variants Previously Associated with Fasting Glucose and Insulin in the Diabetes Prevention Program. <i>PLoS ONE</i> , 2012, 7, e44424.	1.1	39
114	A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. <i>Nature Genetics</i> , 2012, 44, 659-669.	9.4	762
115	Pharmacogenetics in type 2 diabetes: potential implications for clinical practice. <i>Genome Medicine</i> , 2011, 3, 76.	3.6	28
116	Genome-Wide Association Identifies Nine Common Variants Associated With Fasting Proinsulin Levels and Provides New Insights Into the Pathophysiology of Type 2 Diabetes. <i>Diabetes</i> , 2011, 60, 2624-2634.	0.3	335
117	Metabolite profiles and the risk of developing diabetes. <i>Nature Medicine</i> , 2011, 17, 448-453.	15.2	2,586
118	Does Metformin Work for Everyone? A Genome-wide Association Study for Metformin Response. <i>Current Diabetes Reports</i> , 2011, 11, 467-469.	1.7	11
119	Meta-analysis of gene-environment interaction: joint estimation of SNP and SNP \times environment regression coefficients. <i>Genetic Epidemiology</i> , 2011, 35, 11-18.	0.6	158
120	CUBN Is a Gene Locus for Albuminuria. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 555-570.	3.0	208
121	Updated Genetic Score Based on 34 Confirmed Type 2 Diabetes Loci Is Associated With Diabetes Incidence and Regression to Normoglycemia in the Diabetes Prevention Program. <i>Diabetes</i> , 2011, 60, 1340-1348.	0.3	172
122	Genetic Risk Reclassification for Type 2 Diabetes by Age Below or Above 50 Years Using 40 Type 2 Diabetes Risk Single Nucleotide Polymorphisms. <i>Diabetes Care</i> , 2011, 34, 121-125.	4.3	165
123	Genetic Predisposition to Long-Term Nondiabetic Deteriorations in Glucose Homeostasis. <i>Diabetes</i> , 2011, 60, 345-354.	0.3	48
124	Physical Activity Attenuates the Influence of FTO Variants on Obesity Risk: A Meta-Analysis of 218,166 Adults and 19,268 Children. <i>PLoS Medicine</i> , 2011, 8, e1001116.	3.9	446
125	Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. <i>Journal of Clinical Investigation</i> , 2011, 121, 1402-1411.	3.9	537
126	Type 2 Diabetes and Genetics, 2010: Translating Knowledge into Understanding. <i>Current Cardiovascular Risk Reports</i> , 2010, 4, 437-445.	0.8	4

#	ARTICLE	IF	CITATIONS
127	Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. <i>Nature Genetics</i> , 2010, 42, 142-148.	9.4	591
128	Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. <i>Nature Genetics</i> , 2010, 42, 579-589.	9.4	1,631
129	Detailed Physiologic Characterization Reveals Diverse Mechanisms for Novel Genetic Loci Regulating Glucose and Insulin Metabolism in Humans. <i>Diabetes</i> , 2010, 59, 1266-1275.	0.3	237
130	Common Variants at 10 Genomic Loci Influence Hemoglobin A1C Levels via Glycemic and Nonglycemic Pathways. <i>Diabetes</i> , 2010, 59, 3229-3239.	0.3	387
131	The genetics of type 2 diabetes: what have we learned from GWAS?. <i>Annals of the New York Academy of Sciences</i> , 2010, 1212, 59-77.	1.8	319
132	Racial/Ethnic Differences in Association of Fasting Glucose-associated Genomic Loci With Fasting Glucose, HOMA-B, and Impaired Fasting Glucose in the U.S. Adult Population. <i>Diabetes Care</i> , 2010, 33, 2370-2377.	4.3	20
133	A Genome-Wide Association Study of Treated A1C: A Genetic Needle in an Environmental Haystack?. <i>Diabetes</i> , 2010, 59, 332-334.	0.3	18
134	Common Variants in 40 Genes Assessed for Diabetes Incidence and Response to Metformin and Lifestyle Intervention in the Diabetes Prevention Program. <i>Diabetes</i> , 2010, 59, 2672-2681.	0.3	234
135	Genetic Susceptibility to Type 2 Diabetes and Implications for Therapy. <i>Journal of Diabetes Science and Technology</i> , 2009, 3, 690-696.	1.3	7
136	Clinical translation of genetic predictors for type 2 diabetes. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2009, 16, 100-106.	1.2	19
137	The Association of ENPP1K121Q with Diabetes Incidence Is Abolished by Lifestyle Modification in the Diabetes Prevention Program. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 449-455.	1.8	48
138	The dawn of prospective pharmacogenetic testing in type 2 diabetes. <i>Current Diabetes Reports</i> , 2009, 9, 95-97.	1.7	0
139	Variants in MTNR1B influence fasting glucose levels. <i>Nature Genetics</i> , 2009, 41, 77-81.	9.4	662
140	Genetic Architecture of Type 2 Diabetes: Recent Progress and Clinical Implications. <i>Diabetes Care</i> , 2009, 32, 1107-1114.	4.3	56
141	Novel genetic findings applied to the clinic in type 2 diabetes. <i>Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion</i> , 2009, 56, 21-25.	0.8	0
142	Genomics of type 2 diabetes mellitus: implications for the clinician. <i>Nature Reviews Endocrinology</i> , 2009, 5, 429-436.	4.3	83
143	Ordered Stratification to Reduce Heterogeneity in Linkage to Diabetes-related Quantitative Traits. <i>Obesity</i> , 2008, 16, 2314-2322.	1.5	4
144	Genetic Susceptibility to Type 2 Diabetes and Implications for Antidiabetic Therapy. <i>Annual Review of Medicine</i> , 2008, 59, 95-111.	5.0	47

#	ARTICLE	IF	CITATIONS
145	Genotype Score in Addition to Common Risk Factors for Prediction of Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2008, 359, 2208-2219.	13.9	696
146	The prevention of type 2 diabetes. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 382-393.	2.9	216
147	Haplotype Structure of the <i>ENPP1</i> Gene and Nominal Association of the K121Q Missense Single Nucleotide Polymorphism With Glycemic Traits in the Framingham Heart Study. <i>Diabetes</i> , 2008, 57, 1971-1977.	0.3	42
148	Extension of Type 2 Diabetes Genome-Wide Association Scan Results in the Diabetes Prevention Program. <i>Diabetes</i> , 2008, 57, 2503-2510.	0.3	93
149	The Genetics of Type 2 Diabetes: A Realistic Appraisal in 2008. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4633-4642.	1.8	109
150	The <i>ENPP1</i> K121Q Polymorphism Is Associated With Type 2 Diabetes in European Populations. <i>Diabetes</i> , 2008, 57, 1125-1130.	0.3	91
151	TCF7L2 Variants Associate with CKD Progression and Renal Function in Population-Based Cohorts. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 1989-1999.	3.0	43
152	Effects of the Type 2 Diabetes-Associated <i>PPARG</i> P12A Polymorphism on Progression to Diabetes and Response to Troglitazone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1502-1509.	1.8	122
153	A 100K Genome-Wide Association Scan for Diabetes and Related Traits in the Framingham Heart Study: Replication and Integration With Other Genome-Wide Datasets. <i>Diabetes</i> , 2007, 56, 3063-3074.	0.3	87
154	Knowledge Is Power. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 1489-90.	3.8	0
155	The new type 2 diabetes gene <i>TCF7L2</i> . <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2007, 10, 391-396.	1.3	96
156	Genome-Wide Association Analysis Identifies Loci for Type 2 Diabetes and Triglyceride Levels. <i>Science</i> , 2007, 316, 1331-1336.	6.0	2,623
157	Genome-wide association with diabetes-related traits in the Framingham Heart Study. <i>BMC Medical Genetics</i> , 2007, 8, S16.	2.1	80
158	Common Single Nucleotide Polymorphisms in <i>TCF7L2</i> Are Reproducibly Associated With Type 2 Diabetes and Reduce the Insulin Response to Glucose in Nondiabetic Individuals. <i>Diabetes</i> , 2006, 55, 2890-2895.	0.3	346
159	<i>TCF7L2</i> Polymorphisms and Progression to Diabetes in the Diabetes Prevention Program. <i>New England Journal of Medicine</i> , 2006, 355, 241-250.	13.9	762
160	Common Variants in the <i>ENPP1</i> Gene Are Not Reproducibly Associated With Diabetes or Obesity. <i>Diabetes</i> , 2006, 55, 3180-3184.	0.3	76
161	The Kruppel-Like Factor 11 (<i>KLF11</i>) Q62R Polymorphism Is Not Associated With Type 2 Diabetes in 8,676 People. <i>Diabetes</i> , 2006, 55, 3620-3624.	0.3	16
162	Haplotype Structures and Large-Scale Association Testing of the 5' AMP-Activated Protein Kinase Genes <i>PRKAA2</i> , <i>PRKAB1</i> , and <i>PRKAB2</i> With Type 2 Diabetes. <i>Diabetes</i> , 2006, 55, 849-855.	0.3	28

#	ARTICLE	IF	CITATIONS
163	High-density haplotype structure and association testing of the insulin-degrading enzyme (IDE) gene with type 2 diabetes in 4,206 people. <i>Diabetes</i> , 2006, 55, 128-35.	0.3	13
164	Association Testing of the Protein Tyrosine Phosphatase 1B Gene (PTPN1) With Type 2 Diabetes in 7,883 People. <i>Diabetes</i> , 2005, 54, 1884-1891.	0.3	49
165	Association Testing in 9,000 People Fails to Confirm the Association of the Insulin Receptor Substrate-1 G972R Polymorphism With Type 2 Diabetes. <i>Diabetes</i> , 2004, 53, 3313-3318.	0.3	78
166	Haplotype Structure and Genotype-Phenotype Correlations of the Sulfonylurea Receptor and the Islet ATP-Sensitive Potassium Channel Gene Region. <i>Diabetes</i> , 2004, 53, 1360-1368.	0.3	284
167	THE INHERITED BASIS OF DIABETES MELLITUS: Implications for the Genetic Analysis of Complex Traits. <i>Annual Review of Genomics and Human Genetics</i> , 2003, 4, 257-291.	2.5	281
168	Genome-Wide Meta-Analysis Identifies the Organic Anion-Transporting Polypeptide Gene &SLCO1B1& and Statins as Modifiers of Glycemic Response to Sulfonylureas. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0